Prostate Cancer Overview PowerPoint Presentation

Slide 1 -

Prostate Cancer Robert R. Zaid D.O Family Medicine 6/23/2010

Slide 2 -

Practice Management Moment How can you expand your practice using social history?

Slide 3 -

ppt slide no 3 content not found

Slide 4 -

Prostate Cancer Definition Relevance Most common noncutaneous malignancy in men Incidence Nearly 200,000 new cases per year in U.S. Mortality 32,000 deaths in the United States each year Second most common cause of cancer death in men2 Morbidity Single histologic disease Ranges From indolent, clinically irrelevant To virulent, rapidly lethal phenotype. Small, E., Cecil Textbook of Medicine, Prostate Cancer, 2004, WB Saunders, an Elsevier imprint Theodorescu, D., Prostate Cancer: Management of Localized Disease, www.emedicine.com, 20042

Slide 5 -

Prostate Cancer Epidemiology Prostate-specific antigen (PSA) assay has affected incidence of prostate cancer Incidence Prior to PSA 19,000 new cases / year in US 1993 84,000 1996 300,000 Since 1996 200,000 per year A number that more closely estimate the true annual incidence of clinically detectable disease Small, E., Cecil Textbook of Medicine, Prostate Cancer, 2004, WB Saunders, an Elsevier imprint

Slide 6 -

Prostate Cancer Epidemiology Death rate Declined by about 1% per year since 1990 Greatest decrease in men younger than age 75 years Men older than 75 years still account for two thirds of all prostate cancer deaths Due to Early detection (screening) or to improved therapy? Small, E., Cecil Textbook of Medicine, Prostate Cancer, 2004, WB Saunders, an Elsevier imprint

Slide 7 -

Prostate Cancer Epidemiology Risk factors Increasing age Family history African-American Dietary factors. Nutritional factors have protective effect against prostate cancer Reduced fat intake Soy protein Lycopene Vitamin E Selenium Race Incidence doubled in African Americans compared to white Americans. Genetics Common among relatives with early-onset prostate cancer Susceptibility locus (early onset prostate cancer) Chromosome 1, band Q24 An abnormality at this locus occurs in less than 10% of prostate cancer patients. Small, E., Cecil Textbook of Medicine, Prostate Cancer, 2004, WB Saunders, an Elsevier imprint

Slide 8 -

Prostate Cancer Anatomy Position Prostate lies below the bladder Encompasses the prostatic urethra Surrounded by a capsule Separated from the rectum Layer of fascia termed the Denonvilliers aponeurosis Blood supply Inferior vesical artery Derived from the internal iliac artery Supplies blood to the base of the bladder and prostate Capsular branches of the inferior vesical artery Help identify the pelvic plexus Arising from the S2-4 and T10-12 nerve roots Nervous supply Neurovascular bundle Lies on either side of the prostate on the rectum Derived from the pelvic plexus Important for erectile function. Theodorescu, D., Prostate Cancer: Management of Localized Disease, www.emedicine.com, 2004

Slide 9 -

Prostate Cancer Pathophysiology Adenocarcinoma 95% of prostate cancers Developing in the acini of prostatic ducts Rare histopathologic types of prostate carcinoma Occur in approximately 5% of patients Include Small cell carcinoma Mucinous carcinoma Endometrioid cancer (prostatic ductal carcinoma) Transitional cell cancer Squamous cell carcinoma Basal cell carcinoma Adenoid cystic carcinoma (basaloid) Signet-ring cell carcinoma Neuroendocrine cancer Theodorescu, D., Prostate Cancer: Management of Localized Disease, www.emedicine.com, 2004

Slide 10 -

Prostate Cancer Pathophysiology Peripheral zone (PZ) 70% of cancers Transitional zone (TZ) 20% Some claim TZ prostate cancers are relatively nonaggressive PZ cancers are more aggressive Tend to invade the periprostatic tissues. Theodorescu, D., Prostate Cancer: Management of Localized Disease, www.emedicine.com, 2004

Slide 11 -

Prostate Cancer Clinical Manifestations Early state (organ confined) Asymptomatic Locally advanced Obstructive voiding symptoms Hesitancy Intermittent urinary stream Decreased force of stream May have growth into the urethra or bladder neck Hematuria Hematospermia Advanced (spread to the regional pelvic lymph nodes) Edema of the lower extremities Pelvic and perineal discomfort Small, E., Cecil Textbook of Medicine, Prostate Cancer, 2004, WB Saunders, an Elsevier imprint

Slide 12 -

Prostate Cancer Clinical Manifestations Metastasis Most commonly to bone (frequently asymptomatic) Can cause severe and unremitting pain Bone metastasis Can result in pathologic fractures or Spinal cord compression Visceral metastases (rare) Can develop pulmonary, hepatic, pleural, peritoneal, and central nervous system metastases late in the natural history or after hormonal therapies fail. Small, E., Cecil Textbook of Medicine, Prostate Cancer, 2004, WB Saunders, an Elsevier imprint

Slide 13 -

Prostate Cancer Detection and Diagnosis PSA level Helpful in asymptomatic patients > 60% of patients with prostate cancer are asymptomatic Diagnosis is made solely because of an elevated screening PSA level A palpable nodule on digital rectal examination Next most common clinical presentation Prompts biopsy Much less commonly, patients are symptomatic Advanced disease Obstructive voiding symptoms Pelvic or perineal discomfort Lower extremity edema Symptomatic bone lesions. Small, E., Cecil Textbook of Medicine, Prostate Cancer, 2004, WB Saunders, an Elsevier imprint

Slide 14 -

Prostate Cancer Detection and Diagnosis Digital rectal examination Low sensitivity and specificity for diagnosis Biopsy of a nodule or area of induration Reveals cancer 50% of the time Suggests Prostate biopsy Should be undertaken in all men with palpable nodules. Small, E., Cecil Textbook of Medicine, Prostate Cancer, 2004, WB Saunders, an Elsevier imprint

Slide 15 -

Prostate Cancer Treatment PSA screening Early detection Large number of nonpalpable tumors Often clinical means of staging are inadequate Emphasis is being placed on PSA and other predictors of outcome Careful risk assessment is required to identify patients who are appropriate candidates for definitive local treatment Small, E., Cecil Textbook of Medicine, Prostate Cancer, 2004, WB Saunders, an Elsevier imprint

Slide 16 -

Prostate Cancer Detection and Diagnosis The PSA level Better sensitivity but a low specificity Benign prostatic hypertrophy and prostatitis Cause false-positive PSA elevations Threshold Using a PSA threshold of 4ng/mL 70 to 80% of tumors are detected Cancer rates range from 4 to 9% Positive predictive value for a single PSA level greater than 10ng/mL > 60% for cancer, Positive predictive value for a PSA level between 4 and 10ng/mL Only about 30%. Small, E., Cecil Textbook of Medicine, Prostate Cancer, 2004, WB Saunders, an Elsevier imprint

Slide 17 -

Prostate Cancer Detection and Diagnosis PSA Velocity Better measure of high risk patients A rate > 0.75/year increase warrants biopsy American College of Surgeons

Slide 18 -

Prostate Cancer Recommendations PSA screening w/ DRE Yearly after age 50 w/ 10 year life expectancy May start at 45 w/ close relative w/ prostate cancer <65 May start at 40 for multiple close relatives w/ prostate cancer <65 USPSTF, AAFP, ACS? Small, E., Cecil Textbook of Medicine, Prostate Cancer, 2004, WB Saunders, an Elsevier imprint

Slide 19 -

Prostate Cancer Detection and Diagnosis Unbound PSA (free) May distinguish prostate cancer from benign processes A PSA level of 4 to 10ng/mL The percentage of free PSA appears to be an independent predictor of prostate cancer A cutoff value of a free PSA less than 25% can detect 95% of cancers while avoiding 20% of unnecessary biopsies. Small, E., Cecil Textbook of Medicine, Prostate Cancer, 2004, WB Saunders, an Elsevier imprint

Slide 20 -

Prostate Cancer Detection and Diagnosis Transrectal ultrasound with biopsies Indicated when The PSA level is elevated The percent-free PSA is less than 25%, or An abnormality is noted on digital rectal examination Type of biopsy Sextant biopsies (base, midgland, and apex on each side) Generally obtained Seminal vesicles are biopsied in high-risk patients Small, E., Cecil Textbook of Medicine, Prostate Cancer, 2004, WB Saunders, an Elsevier imprint

Slide 21 -

Prostate Cancer Detection and Diagnosis A bone scan Warranted only PSA level greater than 10ng/mL Computed Tomography or magnetic resonance imaging Abdominal and pelvic CT or MRI is usually unrevealing in patients with a PSA level less than 20ng/mL. . Small, E., Cecil Textbook of Medicine, Prostate Cancer, 2004, WB Saunders, an Elsevier imprint

Slide 22 -

Prostate Cancer Prognosis Prognosis correlates with histologic grade and extent (stage) of disease Adenocarcinoma > 95% of prostate cancers Multifocality is common Grading Ranges from 1 to 5 Gleason score Definition Sum of the two most common histologic patterns seen on each tissue specimen Ranges From 2 (1 + 1) To 10 (5 + 5) Category Well-differentiated (Gleason scores 2, 3, or 4) Intermediate differentiation (Gleason scores 5, 6, or 7) Poorly differentiated (Gleason scores 8, 9, or 10). Small, E., Cecil Textbook of Medicine, Prostate Cancer, 2004, WB Saunders, an Elsevier imprint

Slide 23 -

Prostate Cancer Prognosis Staging Definition Extent of disease determined by Physical examination Imaging studies Pathology Small, E., Cecil Textbook of Medicine, Prostate Cancer, 2004, WB Saunders, an Elsevier imprint

Slide 24 -

Prostate Cancer Staging Stage T1 Nonpalpable prostate cancer Detected only on pathologic examination Incidentally noted after Transurethral resection for benign hypertrophy (T1a and T1b) or On biopsy obtained because of an elevated PSA (T1c-the most common clinical stage at diagnosis) Stage T2 Palpable tumor Appears to be confined to the prostatic gland (T2a if one lobe, T2b if two lobes) Stage T3 Tumor with extension through the prostatic capsule (T2a if focal, T2b if seminal vesicles are involved) Stage T4 Invasion of adjacent structures Bladder neck External urinary sphincter The rectum The levator muscles The pelvic sidewal Nodal metastases Can be microscopic and can be detected only by biopsy or lymphadenectomy, or they can be visible on imaging studies Distant metastases Predominantly to bone Occasional visceral metastases occur. Small, E., Cecil Textbook of Medicine, Prostate Cancer, 2004, WB Saunders, an Elsevier imprint

Slide 25 -

Prostate Cancer Treatment PRINCIPLES OF THERAPY May include Watchful waiting Androgen deprivation External beam radiotherapy Retropubic or perineal radical prostatectomy with or without postoperative radiotherapy to the prostate margins and pelvis Brachytherapy (either permanent or temporary radioactive seed implants) with or without external beam radiotherapy to the prostate margins and pelvis. Small, E., Cecil Textbook of Medicine, Prostate Cancer, 2004, WB Saunders, an Elsevier imprint

Slide 26 -

Prostate Cancer Treatment Require individualization Must take into account Patient's comorbidity Life expectancy Likelihood of cure Personal preferences Based on an understanding of potential morbidity associated with each treatment A multidisciplinary approach (recommended) Integrate Surgery Radiation therapy Androgen deprivation Behavioral therapy Small, E., Cecil Textbook of Medicine, Prostate Cancer, 2004, WB Saunders, an Elsevier imprint

Slide 27 -

Prostate Cancer Treatment Surgery Traditional Robotic Radiation Brachytherapy External beam Cryotherapy Androgen Deprivation Watchful waiting Small, E., Cecil Textbook of Medicine, Prostate Cancer, 2004, WB Saunders, an Elsevier imprint

Slide 28 -

Prostate Cancer Treatment - LOW/INTERMEDIATE RISK DISEASE LOW/INTERMEDIATE RISK DISEASE Randomized trial Under the age of 75 Clinical stage T1b, T1c, or T2 prostate cancer Radical prostatectomy Reduced the relative risk of death by 50% (a 2% absolute risk reduction) Compared with watchful waiting Despite a significant reduction in the risk of metastasis, overall mortality was unchanged Adverse effects on quality of life More dysfunction and urinary leakage after radical prostatectomy More urinary obstruction with watchful waiting Nerve-sparing radical prostatectomy was not routinely performed in this study Less advanced disease with newer surgical techniques are not known Small, E., Cecil Textbook of Medicine, Prostate Cancer, 2004, WB Saunders, an Elsevier imprint

Slide 29 -

Prostate Cancer Treatment - LOW/INTERMEDIATE RISK DISEASE Nonrandomized data Suggest that watchful waiting may be judiciously used Gleason score 2, 3, or 4 tumors with life expectancy of 10 years or less Watchful waiting is probably not appropriate for young, otherwise healthy men with high-risk features as described earlier (PSA > 10, Gleason sum = 7, or clinical stage T3 or higher). Small, E., Cecil Textbook of Medicine, Prostate Cancer, 2004, WB Saunders, an Elsevier imprint

Slide 30 -

Prostate Cancer Treatment - LOW/INTERMEDIATE RISK DISEASE Androgen deprivation has not been carefully studied as primary therapy for localized disease More common approach in some men To receive some therapy when not suited for or decline prostatectomy or radiation therapy. Surgery or radiation Men with T1 or T2 prostate cancer Life expectancy of more than 10 years No significant comorbid illnesses Long-term survival is excellent Small, E., Cecil Textbook of Medicine, Prostate Cancer, 2004, WB Saunders, an Elsevier imprint

Slide 31 -

Prostate Cancer Treatment - LOW/INTERMEDIATE RISK DISEASE T1 or T2 tumors Gleason scores of 7 or less Have 8-year survival rates of 85 to 95%. Gleason scores of 8 to 10 Have 8-year survival rates of about 70%. Small, E., Cecil Textbook of Medicine, Prostate Cancer, 2004, WB Saunders, an Elsevier imprint

Slide 32 -

Prostate Cancer Treatment - LOW/INTERMEDIATE RISK DISEASE Nerve-sparing procedures and careful dissection techniques Decreased postoperative complications Urinary incontinence (<10%) Impotence (10-50%) Following a radical prostatectomy PSA should become undetectable Detectable PSA implies Presence of cancer cells Locally or at a metastatic site Adjuvant postoperative radiotherapy is of unproven benefit unless the PSA remains or becomes detectable. Small, E., Cecil Textbook of Medicine, Prostate Cancer, 2004, WB Saunders, an Elsevier imprint

Slide 33 -

Prostate Cancer Treatment - LOW/INTERMEDIATE RISK DISEASE External beam radiation therapy (EBRT) Three-dimensional conformal radiation therapy (3D-CRT) (replacing EBRT) Higher doses to the target tissue Less toxicity Randomized trials are required to assess any clinical benefits Complications of external radiotherapy Cystitis Proctitis Enteritis Impotence Urinary retention Incontinence (7-10%) Small, E., Cecil Textbook of Medicine, Prostate Cancer, 2004, WB Saunders, an Elsevier imprint

Slide 34 -

Prostate Cancer Treatment - LOW/INTERMEDIATE RISK DISEASE Brachytherapy Placement of permanent or temporary radioactive seeds directly into the prostate Adequate for Intracapsular disease No more than minimal transcapsular extension It can be combined with external beam radiation therapy. Small, E., Cecil Textbook of Medicine, Prostate Cancer, 2004, WB Saunders, an Elsevier imprint

Slide 35 -

Prostate Cancer Treatment – High-risk disease HIGH-RISK DISEASE. Patients with adverse risk features (Gleason score 8 to 10, PSA > 10, stage T3) Treated with Aggressive local therapy or Androgen deprivation Synergistic with radiation therapy Trials 4 months of androgen deprivation with radiation therapy Improve local control and prolong progression-free survival in patients with intermediate risk features Long-term androgen deprivation (up to 3 years) Prolongs local control Prolongs progression-free survival and overall survival in patients with high-risk features compared with radiation therapy. Small, E., Cecil Textbook of Medicine, Prostate Cancer, 2004, WB Saunders, an Elsevier imprint

Slide 36 -

Prostate Cancer Treatment – Recurrent disease RECURRENT DISEASE ~50% of men treated with radiation therapy or prostatectomy develop evidence of recurrence Defined by a climbing PSA level Local salvage therapy Selected patients with clear local recurrences Surgery for patients previously treated with radiation Radiation for patients previously treated with surgery and androgen deprivation Early hormone therapy Appears to be better than hormonal salvage therapy in terms of survival. Small, E., Cecil Textbook of Medicine, Prostate Cancer, 2004, WB Saunders, an Elsevier imprint

Slide 37 -

Prostate Cancer Treatment – Advanced disease ADVANCED DISEASE Microscopic involvement of lymph nodes Revealed by radical prostatectomy Immediate androgen deprivation prolongs survival Should not wait until osseous metastases are detected Patients at high risk of nodal invasion and who undergo external beam radiation Benefit from concurrent short-term hormonal therapy. Newly diagnosed metastatic prostate cancer Androgen deprivation is the mainstay of treatment Results in symptomatic improvement and disease regression in approximately 80 to 90% of patients Androgen deprivation can be achieved by orchiectomy or by medical castration Luteinizing hormone-releasing hormone (LHRH) agonist (leuprolide acetate, goserelin acetate) Safer and as effective as estrogen treatment. Small, E., Cecil Textbook of Medicine, Prostate Cancer, 2004, WB Saunders, an Elsevier imprint

Slide 38 -

Prostate Cancer Treatment – Advanced disease Side effects of LHRH agonist LH and testosterone surge within 72 hours Transient worsening of signs and symptoms during the first week of therapy An antiandrogen (flutamide, bicalutamide, or nilutamide) should be given with the first LHRH injection to prevent a tumor flare Medical castration occurs within 4 weeks Hormone sensitivity Duration 5 to 10 years for node-positive or high-risk localized (or recurrent) prostate cancer 18 to 24 months in patients with overt metastatic disease Side effects androgen ablation Loss of libido Impotence Hot flashes Weight gain Fatigue Anemia Osteoporosis Bisphosphonates reduce bone mineral loss associated with androgen deprivation. Small, E., Cecil Textbook of Medicine, Prostate Cancer, 2004, WB Saunders, an Elsevier imprint

Slide 39 -

Prostate Cancer Treatment – Hormone resistant HORMONE-RESISTANT PROSTATE CANCER Climbing PSA First manifestation of resistance to androgen deprivation In the setting of anorchid levels of testosterone Therapy Discontinuation of antiandrogen therapy (flutamide, bicalutamide, nilutamide) while continuing with LHRH agonists Results in a PSA decline Can be associated with symptomatic improvement Can persist for 4 to 24 months or more Secondary hormonal manipulations Ketoconazole or Estrogens Chemotherapeutic regimens Mitoxantrone plus corticosteroids or Estramustine plus a taxane Monitoring Serial PSA levels (best) A decline of 50% or more is probably clinically significant Small, E., Cecil Textbook of Medicine, Prostate Cancer, 2004, WB Saunders, an Elsevier imprint

Slide 40 -

Prostate Cancer Treatment – Hormone resistant PALLIATIVE CARE Bone pain Advanced prostate cancer Analgesics Glucocorticoids Anti-inflammatory agents Can alleviate bone pain Widespread bony metastases not easily controlled with analgesics or local radiation Strontium-89 and samarium-153 Selectively concentrated in bone metastases Alleviate pain in 70% or more of treated patients. Small, E., Cecil Textbook of Medicine, Prostate Cancer, 2004, WB Saunders, an Elsevier imprint

Slide 41 -

Prostate Cancer Prognosis PROGNOSIS Gleason 2-4 10-year PSA progression-free survival is 70 to 80% Treated with radiation therapy or surgery 5-7 50 to 70% 8-10 15 to 30% Climbing PSA after radical prostatectomy Prognostic variables Time to detectable PSA Gleason score at the time of prostatectomy PSA doubling time Small, E., Cecil Textbook of Medicine, Prostate Cancer, 2004, WB Saunders, an Elsevier imprint

Slide 42 -

Any questions? Can be found at www.drzaid.com/documents/prostate.ppt